Mizuho Upgrades Belite Bio to Outperform, Raises Price Target to $194
Benzinga Newsdesk 11 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Mizuho analyst Graig Suvannavejh upgrades Belite Bio (NASDAQ:BLTE) from Neutral to Outperform and raises the price target from $105 to $194.
Mizuho analyst Graig Suvannavejh upgrades Belite Bio (NASDAQ:BLTE) from Neutral to Outperform and raises the price target from $105 to $194.